CA2291233A1 - Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents - Google Patents

Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents Download PDF

Info

Publication number
CA2291233A1
CA2291233A1 CA002291233A CA2291233A CA2291233A1 CA 2291233 A1 CA2291233 A1 CA 2291233A1 CA 002291233 A CA002291233 A CA 002291233A CA 2291233 A CA2291233 A CA 2291233A CA 2291233 A1 CA2291233 A1 CA 2291233A1
Authority
CA
Canada
Prior art keywords
bergamottin
oral bioavailability
increasing
compositions containing
pharmaceutical agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002291233A
Other languages
French (fr)
Other versions
CA2291233C (en
Inventor
Kan He
Paul Frederick Hollenberg
Thomas Francis Woolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner-Lambert Company
Kan He
Paul Frederick Hollenberg
Thomas Francis Woolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, Kan He, Paul Frederick Hollenberg, Thomas Francis Woolf filed Critical Warner-Lambert Company
Publication of CA2291233A1 publication Critical patent/CA2291233A1/en
Application granted granted Critical
Publication of CA2291233C publication Critical patent/CA2291233C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Bergamottin, a principle compound in grapefruit juice responsible for inhibition of P450 3A4, the predominant P450 enzyme in the intestine, is coadministered with a compound having low bioavailability to a patient to increase oral bioavailability of the compound and pharmaceutical compositions of the same, as well as a method of isolating BG
from grapefruit juice.
CA002291233A 1997-08-19 1998-08-11 Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents Expired - Fee Related CA2291233C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5612997P 1997-08-19 1997-08-19
US60/056,129 1997-08-19
PCT/US1998/016579 WO1999008676A1 (en) 1997-08-19 1998-08-11 Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents

Publications (2)

Publication Number Publication Date
CA2291233A1 true CA2291233A1 (en) 1999-02-25
CA2291233C CA2291233C (en) 2006-10-10

Family

ID=22002350

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002291233A Expired - Fee Related CA2291233C (en) 1997-08-19 1998-08-11 Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents

Country Status (15)

Country Link
US (1) US6509371B1 (en)
EP (1) EP1007034B1 (en)
JP (1) JP2001515035A (en)
KR (1) KR100510809B1 (en)
AT (1) ATE253357T1 (en)
AU (1) AU747051B2 (en)
BR (1) BR9812131A (en)
CA (1) CA2291233C (en)
DE (1) DE69819519T2 (en)
DK (1) DK1007034T3 (en)
ES (1) ES2209184T3 (en)
NZ (1) NZ502668A (en)
PT (1) PT1007034E (en)
WO (1) WO1999008676A1 (en)
ZA (1) ZA987436B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1014575A3 (en) * 2002-01-16 2004-01-13 Chapelle Andre COMPOSITION CONTAINING 5.7 DMC AND / OR bergamottin.
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
JP5064036B2 (en) 2005-01-21 2012-10-31 アークレイ株式会社 Metabolic syndrome improving agent, and medicine, supplement, functional food and food additive containing the same
JP4902964B2 (en) * 2005-03-30 2012-03-21 株式会社ファンケル Drug metabolism inhibitors and their use
CA2913023C (en) 2013-05-30 2021-06-08 Nanobiotix Pharmaceutical composition, preparation and uses thereof
AR102781A1 (en) 2014-11-25 2017-03-22 Nanobiotix PHARMACEUTICAL COMPOSITION THAT COMBINES AT LEAST TWO DIFFERENT NANOPARTICLES AND A PHARMACEUTICAL COMPOUND, ITS PREPARATION AND ITS USES
US11304902B2 (en) * 2014-11-25 2022-04-19 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof
KR101729494B1 (en) 2015-06-29 2017-04-25 제주대학교 산학협력단 Cosmetic composition containing 6,7-dihydroxy bergamottin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2996838B2 (en) * 1993-07-12 2000-01-11 株式会社ポッカコーポレーション Antibacterial agent
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
JPH11507356A (en) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド Use of essential oils to enhance the bioavailability of oral pharmacological compounds
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO1998017667A1 (en) * 1996-10-18 1998-04-30 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice

Also Published As

Publication number Publication date
KR100510809B1 (en) 2005-08-31
EP1007034A1 (en) 2000-06-14
WO1999008676A1 (en) 1999-02-25
ATE253357T1 (en) 2003-11-15
ZA987436B (en) 1999-02-22
US6509371B1 (en) 2003-01-21
ES2209184T3 (en) 2004-06-16
AU747051B2 (en) 2002-05-09
BR9812131A (en) 2000-07-18
DK1007034T3 (en) 2004-03-22
JP2001515035A (en) 2001-09-18
DE69819519T2 (en) 2004-09-23
EP1007034B1 (en) 2003-11-05
KR20010023034A (en) 2001-03-26
AU8777098A (en) 1999-03-08
PT1007034E (en) 2004-03-31
NZ502668A (en) 2001-10-26
DE69819519D1 (en) 2003-12-11
CA2291233C (en) 2006-10-10

Similar Documents

Publication Publication Date Title
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
CA2330128A1 (en) Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
AP1253A (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate.
CA2312936A1 (en) Compositions and methods for weight reduction
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
WO2001019356A3 (en) High lipid diet
WO2000078294A3 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
MY118156A (en) Oral compositions of levosimendan.
AU5911994A (en) Oral formulations of ubidecarenone in the form of capsules
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
CA2291233A1 (en) Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
CA2386770A1 (en) Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
IL132992A0 (en) Method and compositions for administering taxanes orally to human patients
CA2179733A1 (en) Anticonvulsant pseudofructopyranose sulfamates
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
CA2386423A1 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
CA2374471A1 (en) Therapeutically and/or nutritionally enhanced derivatives of active ingredients and orally administrable compositions containing same
IL108246A (en) (all-e)-3,7-dimethyl-9-(3, 5-dimethyl- 2-nonyloxyphenyl)-2, 4, 6, 8-nonatetraenoic acid derivatives, their preparation and pharmaceutical compositions containing them
AU7678900A (en) Liquid nutritional supplement composition and method of preparation
CA2075926A1 (en) Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed